Us Congress 2025-2026 Regular Session

Us Congress House Bill HB1266 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	I
2	2	119THCONGRESS
3	3	1
4	4	STSESSION H. R. 1266
5	5	To prohibit certain uses of xylazine, and for other purposes.
6	6	IN THE HOUSE OF REPRESENTATIVES
7	7	FEBRUARY12, 2025
8	8	Mr. P
9	9	ANETTA(for himself, Mr. PFLUGER, Mr. BILIRAKIS, Mr. PAPPAS, Mr.
10	10	F
11	11	ITZGERALD, Ms. ROSS, Mr. CRENSHAW, Mr. HARDERof California, Ms.
12	12	D
13	13	ELBENE, Mrs. MILLER-MEEKS, Ms. PETTERSEN, Ms. CLARKEof New
14	14	York, Mr. D
15	15	ELUZIO, Mr. MAGAZINER, Mr. BACON, Mr. OBERNOLTE, Mr.
16	16	C
17	17	OSTA, Mr. BALDERSON, Ms. BARRAGA´N, Mr. CISCOMANI, Mr. CAREY,
18	18	Mrs. B
19	19	ICE, Ms. CRAIG, Mr. NORCROSS, Mr. FONG, Ms. TENNEY, Mr.
20	20	F
21	21	ITZPATRICK, Mr. BURCHETT, Ms. DEANof Pennsylvania, Mr. COHEN,
22	22	Mr. D
23	23	AVISof North Carolina, Mr. CORREA, Mr. WEBSTERof Florida,
24	24	Mr. C
25	25	OLLINS, Mr. SUOZZI, and Mrs. HARSHBARGER) introduced the fol-
26	26	lowing bill; which was referred to the Committee on Energy and Com-
27	27	merce, and in addition to the Committee on the Judiciary, for a period
28	28	to be subsequently determined by the Speaker, in each case for consider-
29	29	ation of such provisions as fall within the jurisdiction of the committee
30	30	concerned
31	31	A BILL
32	32	To prohibit certain uses of xylazine, and for other purposes.
33	33	Be it enacted by the Senate and House of Representa-1
34	34	tives of the United States of America in Congress assembled, 2
35	35	SECTION 1. SHORT TITLE. 3
36	36	This title may be cited as the ‘‘Combating Illicit 4
37	37	Xylazine Act’’. 5
38	38	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\H1266.IH H1266
39	39	kjohnson on DSK7ZCZBW3PROD with $$_JOB 2
40	40	•HR 1266 IH
41	41	SEC. 2. DEFINITIONS. 1
42	42	(a) I
43	43	NGENERAL.—In this title, the term ‘‘xylazine’’ 2
44	44	has the meaning given the term in paragraph (60) of sec-3
45	45	tion 102 of the Controlled Substances Act, as added by 4
46	46	subsection (b) of this section. 5
47	47	(b) C
48	48	ONTROLLEDSUBSTANCESACT.—Section 102 of 6
49	49	the Controlled Substances Act (21 U.S.C. 802) is amend-7
50	50	ed by adding at the end the following: 8
51	51	‘‘(60) The term ‘xylazine’ means the substance 9
52	52	xylazine, including its salts, isomers, and salts of isomers 10
53	53	whenever the existence of such salts, isomers, and salts 11
54	54	of isomers is possible.’’. 12
55	55	SEC. 3. ADDING XYLAZINE TO SCHEDULE III. 13
56	56	Schedule III of section 202(c) of the Controlled Sub-14
57	57	stances Act (21 U.S.C. 812) is amended by adding at the 15
58	58	end the following: 16
59	59	‘‘(f) Unless specifically excepted or unless listed in 17
60	60	another schedule, any material, compound, mixture, or 18
61	61	preparation which contains any quantity of xylazine.’’. 19
62	62	SEC. 4. AMENDMENTS. 20
63	63	(a) A
64	64	MENDMENT.—Section 102 of the Controlled 21
65	65	Substances Act (21 U.S.C. 802) is amended by striking 22
66	66	paragraph (27) and inserting the following: 23
67	67	‘‘(27)(A) Except as provided in subparagraph (B), 24
68	68	the term ‘ultimate user’ means a person who has lawfully 25
69	69	obtained, and who possesses, a controlled substance for 26
70	70	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\H1266.IH H1266
71	71	kjohnson on DSK7ZCZBW3PROD with $$_JOB 3
72	72	•HR 1266 IH
73	73	the use by the person or for the use of a member of the 1
74	74	household of the person or for an animal owned by the 2
75	75	person or by a member of the household of the person. 3
76	76	‘‘(B)(i) In the case of xylazine, other than for a drug 4
77	77	product approved under subsection (b) or (j) of section 5
78	78	505 of the Federal Food, Drug, and Cosmetic Act (21 6
79	79	U.S.C. 355), the term ‘ultimate user’ means a person— 7
80	80	‘‘(I) to whom xylazine was dispensed by— 8
81	81	‘‘(aa) a veterinarian registered under this 9
82	82	Act; or 10
83	83	‘‘(bb) a pharmacy registered under this 11
84	84	Act pursuant to a prescription of a veterinarian 12
85	85	registered under this Act; and 13
86	86	‘‘(II) who possesses xylazine for— 14
87	87	‘‘(aa) an animal owned by the person or by 15
88	88	a member of the household of the person; 16
89	89	‘‘(bb) an animal under the care of the per-17
90	90	son; 18
91	91	‘‘(cc) use in government animal-control 19
92	92	programs authorized under applicable Federal, 20
93	93	State, Tribal, or local law; or 21
94	94	‘‘(dd) use in wildlife programs authorized 22
95	95	under applicable Federal, State, Tribal, or local 23
96	96	law. 24
97	97	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\H1266.IH H1266
98	98	kjohnson on DSK7ZCZBW3PROD with $$_JOB 4
99	99	•HR 1266 IH
100	100	‘‘(ii) In this subparagraph, the term ‘person’ in-1
101	101	cludes— 2
102	102	‘‘(I) a government agency or business where 3
103	103	animals are located; and 4
104	104	‘‘(II) an employee or agent of an agency or 5
105	105	business acting within the scope of their employment 6
106	106	or agency.’’. 7
107	107	(b) F
108	108	ACILITIES.—An entity that manufactures 8
109	109	xylazine, as of the date of enactment of this Act, shall 9
110	110	not be required to make capital expenditures necessary to 10
111	111	install the security standard required of schedule III of 11
112	112	the Controlled Substances Act (21 U.S.C. 801 et seq.) for 12
113	113	the purposes of manufacturing xylazine. 13
114	114	(c) L
115	115	ABELING.—The requirements related to label-14
116	116	ing, packaging, and distribution logistics of a controlled 15
117	117	substance in schedule III of section 202(c) of the Con-16
118	118	trolled Substances Act (21 U.S.C. 812(c)) shall not take 17
119	119	effect for xylazine until the date that is 1 year after the 18
120	120	date of enactment of this Act. 19
121	121	(d) P
122	122	RACTITIONERREGISTRATION.—The require-20
123	123	ments related to practitioner registration, inventory, and 21
124	124	recordkeeping of a controlled substance in schedule III of 22
125	125	section 202(c) of the Controlled Substances Act (21 23
126	126	U.S.C. 812(c)) shall not take effect for xylazine until the 24
127	127	date that is 60 days after the date of enactment of this 25
128	128	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\H1266.IH H1266
129	129	kjohnson on DSK7ZCZBW3PROD with $$_JOB 5
130	130	•HR 1266 IH
131	131	Act. A practitioner that has applied for registration during 1
132	132	the 60-day period beginning on the date of enactment of 2
133	133	this Act may continue their lawful activities until such ap-3
134	134	plication is approved or denied. 4
135	135	(e) M
136	136	ANUFACTURER TRANSITION.—The Food and 5
137	137	Drug Administration and the Drug Enforcement Adminis-6
138	138	tration shall facilitate and expedite the relevant manufac-7
139	139	turer submissions or applications required by the place-8
140	140	ment of xylazine on schedule III of section 202(c) of the 9
141	141	Controlled Substances Act (21 U.S.C. 812(c)). 10
142	142	(f) C
143	143	LARIFICATION.—Nothing in this title, or the 11
144	144	amendments made by this title, shall be construed to re-12
145	145	quire the registration of an ultimate user of xylazine under 13
146	146	the Controlled Substances Act (21 U.S.C. 801 et seq.) in 14
147	147	order to possess xylazine in accordance with subparagraph 15
148	148	(B) of section 102(27) of that Act (21 U.S.C. 802(27)), 16
149	149	as added by subsection (a) of this section. 17
150	150	SEC. 5. ARCOS TRACKING. 18
151	151	Section 307(i) of the Controlled Substances Act (21 19
152	152	U.S.C. 827(i)) is amended— 20
153	153	(1) in the matter preceding paragraph (1)— 21
154	154	(A) by inserting ‘‘or xylazine’’ after 22
155	155	‘‘gamma hydroxybutyric acid’’; 23
156	156	(B) by inserting ‘‘or 512’’ after ‘‘section 24
157	157	505’’; and 25
158	158	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\H1266.IH H1266
159	159	kjohnson on DSK7ZCZBW3PROD with $$_JOB 6
160	160	•HR 1266 IH
161	161	(C) by inserting ‘‘respectively,’’ after ‘‘the 1
162	162	Federal Food, Drug, and Cosmetic Act,’’; and 2
163	163	(2) in paragraph (6), by inserting ‘‘or xylazine’’ 3
164	164	after ‘‘gamma hydroxybutyric acid’’. 4
165	165	SEC. 6. SENTENCING COMMISSION. 5
166	166	Pursuant to its authority under section 994(p) of title 6
167	167	28, United States Code, the United States Sentencing 7
168	168	Commission shall review and, if appropriate, amend its 8
169	169	sentencing guidelines, policy statements, and official com-9
170	170	mentary applicable to persons convicted of an offense 10
171	171	under section 401 of the Controlled Substances Act (21 11
172	172	U.S.C. 841) or section 1010 of the Controlled Substances 12
173	173	Import and Export Act (21 U.S.C. 960) to provide appro-13
174	174	priate penalties for offenses involving xylazine that are 14
175	175	consistent with the amendments made by this title. In car-15
176	176	rying out this section, the Commission should consider the 16
177	177	common forms of xylazine as well as its use alongside 17
178	178	other scheduled substances. 18
179	179	SEC. 7. REPORT TO CONGRESS ON XYLAZINE. 19
180	180	(a) I
181	181	NITIALREPORT.—Not later than 18 months 20
182	182	after the date of the enactment of this Act, the Attorney 21
183	183	General, acting through the Administrator of the Drug 22
184	184	Enforcement Administration and in coordination with the 23
185	185	Commissioner of Food and Drugs, shall submit to Con-24
186	186	gress a report on the prevalence of illicit use of xylazine 25
187	187	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\H1266.IH H1266
188	188	kjohnson on DSK7ZCZBW3PROD with $$_JOB 7
189	189	•HR 1266 IH
190	190	in the United States and the impacts of such use, includ-1
191	191	ing— 2
192	192	(1) where the drug is being diverted; 3
193	193	(2) where the drug is originating; and 4
194	194	(3) whether any analogues to xylazine, or re-5
195	195	lated or derivative substances, exist and present a 6
196	196	substantial risk of abuse. 7
197	197	(b) A
198	198	DDITIONALREPORT.—Not later than 4 years 8
199	199	after the date of the enactment of this Act, the Attorney 9
200	200	General, acting through the Administrator of the Drug 10
201	201	Enforcement Administration and in coordination with the 11
202	202	Commissioner of Food and Drugs, shall submit to Con-12
203	203	gress a report updating Congress on the prevalence and 13
204	204	proliferation of xylazine trafficking and misuse in the 14
205	205	United States. 15
206	206	Æ
207	207	VerDate Sep 11 2014 22:27 Mar 10, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6301 E:\BILLS\H1266.IH H1266
208	208	kjohnson on DSK7ZCZBW3PROD with $$_JOB